Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Tuesday, March 31, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -636.18%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-244.72%
RETURN ON EQUITY (ROE) AVG 3Y
-155.14%
RETURN ON EQUITY (ROE) AVG 5Y
-144.42%
RETURN ON EQUITY (ROE) AVG 10Y
-113.11%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Skye Bioscience, Inc.
Market Cap
$7.29M
Return on Equity (ROE)
N/A
TTM Avg
-244.72%
3Y Avg
-155.14%
5Y Avg
-144.42%
Market Cap
$7.25M
Return on Equity (ROE)
-1168.44%
TTM Avg
-606.51%
3Y Avg
-330.90%
5Y Avg
-270.23%
Market Cap
$7.21M
Return on Equity (ROE)
-225.67%
TTM Avg
-236.53%
3Y Avg
-220.64%
5Y Avg
-186.37%
Market Cap
$7.13M
Return on Equity (ROE)
-120.58%
TTM Avg
-99.12%
3Y Avg
-428.18%
5Y Avg
-321.37%
Market Cap
$7.07M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$7.55M
Return on Equity (ROE)
-85.24%
TTM Avg
23.31%
3Y Avg
-10.41%
5Y Avg
-27.01%
Market Cap
$7.13M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
Market Cap
$6.95M
Return on Equity (ROE)
-847.90%
TTM Avg
-134.62%
3Y Avg
-211.14%
5Y Avg
-242.56%
Market Cap
$7.02M
Return on Equity (ROE)
N/A
TTM Avg
158.93%
3Y Avg
168.21%
5Y Avg
33.14%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | $7.29M | N/A | -244.72% | -155.14% | -144.42% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -1168.44% | -606.51% | -330.90% | -270.23% |
| Longeveron Inc. (LGVN)vs › | $7.21M | -225.67% | -236.53% | -220.64% | -186.37% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.13M | -120.58% | -99.12% | -428.18% | -321.37% |
| KALA BIO, Inc. (KALA)vs › | $7.07M | -111.46% | -348.97% | -374.13% | -408.25% |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.55M | -85.24% | 23.31% | -10.41% | -27.01% |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | -370.16% | -148.31% | -87.53% | -43.20% |
| Exicure, Inc. (XCUR)vs › | $6.95M | -847.90% | -134.62% | -211.14% | -242.56% |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A | 158.93% | 168.21% | 33.14% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.94M | -227.37% | -118.13% | -87.25% | -55.09% |
ROE
N/A
ROA
-457.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -636.18% |
| 2025-12-31 | -279.29% |
| 2025-09-30 | -156.01% |
| 2025-06-30 | -97.02% |
| 2025-03-31 | -55.11% |
| 2024-12-31 | -38.98% |
| 2024-09-30 | -28.02% |
| 2024-06-30 | -58.08% |
| 2024-03-31 | -47.53% |
| 2022-03-31 | -316.34% |
| 2021-12-31 | -145.33% |
| 2021-09-30 | -90.89% |
| 2021-06-30 | -307.49% |
| 2021-03-31 | -257.38% |
| 2020-09-30 | -11.14% |
| 2019-12-31 | 191.96% |
| 2015-09-30 | -570.36% |
| 2014-04-30 | -21.50% |
| 2014-01-31 | -0.22% |
| 2013-10-31 | -4.38% |
| 2013-07-31 | 9.53% |
| 2013-04-30 | 10.58% |
